This growing interest can be visualized in the nascent field of AllergoOncology, as well as through the recent completion of the Phase I clinical trial of the first-in-class monoclonal IgE antibody (MOv18 IgE) specific for the tumor-associated antigen Folate Receptor alpha (FRα) (NCT02546921) which validated the safety of IgE as a novel cancer treatment as well as demonstrating preliminary anti-tumor efficacy [10]. This evidence concerns the gene FOLR1 and cancer.